VEGF-binding protein for blockade of angiogenesis

US10259862B2 · kind B2 · utility

Assignees

• Children's Medical Center Corporation · US
• The General Hospital Corporation · US
• President and Fellows of Harvard College · US

Inventors

• Bob Carter · San Diego, US
• Jeng-Shin Lee · Lincoln, US
• Szofia S. Bullain · Tustin, US
• Richard C. Mulligan · Cambridge, US

Key dates

• Filing date: Jun 12, 2017
• Grant date: Apr 16, 2019
• Expiry date: Jun 12, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N15/1136
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are chimeric VEGF-binding proteins and nucleic acids (e.g., a vector) encoding chimeric VEGF-binding proteins, methods and host cells for producing these proteins and nucleic acids, and pharmaceutical compositions containing these proteins and nucleic acids. Also provided are methods of treating an angiogenic disease or disorder that include administering at least one of the chimeric VEGF-binding proteins or at least one of the nucleic acids (e.g., a vector) encoding a chimeric VEGF-binding protein.